The team at Third Harmonic Bio is on a mission — we are driven to advance the next wave of medicine for allergy and inflammation. We are grounded in our purpose: developing a medicine that can meaningfully improve the lives of the patients we serve. We cultivate transparency and accessibility, with the knowledge that we can only achieve great things if we are in this together. And we keep going. Because we have something important to offer. And if it were easy, everyone would do it. Come join us.
Our lead program, THB-001, is a potent and highly selective, oral small molecule inhibitor of KIT, the master regulator of mast cell function and survival. Mast cells have long been known to be the central driver of allergic inflammatory processes. By inhibiting KIT, THB-001 has been shown to inactivate and deplete mast cells in multiple preclinical models and early clinical trials, providing the potential for broad symptomatic relief across a range of inflammatory diseases.
With “pipeline-in-a-product” potential, THB-001 is entering Phase 1b clinical trials for chronic urticaria, a dermatologic disease affecting up to 1% of the population that is driven by mast cell activation, resulting in red, itchy, painful welts or hives that can severely impact patients’ quality of life.
Our singular purpose is to create a breakthrough treatment for people living with severe allergy and inflammation—debilitating conditions that can take a significant toll on patients’ overall health and well-being.
Our values provide the scaffolding for our culture and our operating principles —with each other, with our collaborators, and with the global medical and patient community at large.
Third Harmonic Bio is led by a proven executive team with a successful track record of building great companies, developing impactful medicines, and delivering value to all stakeholders: our patients, our employees, and our shareholders.
Edward R. Conner, M.D.
Gregg Keaney, Ph.D.
Adrian S. Ray
David Bonita, M.D.
Mark Iwicki (Chairman)
Shao-Lee Lin, M.D., Ph.D.
Martin Seidel, Ph.D.
Thomas M. Soloway
Mast cells are the primary effector cells of allergic-inflammatory diseases of the skin and respiratory, which collectively affect millions of people worldwide. In their most severe forms, these diseases are associated with significant morbidity. Despite significant investment in the field and the availability of several approved therapies, there remains a significant unmet need in the treatment of these diseases.
Targeting mast cells directly through highly selective inhibition of KIT represents a novel therapeutic approach and may be key to achieving the clinical efficacy needed for broad symptomatic relief across a range of allergic and other inflammatory disorders. The ideal therapeutic profile would combine the target selectivity and potency of a biologic with the ease of administration that an oral small molecule affords.
THB001 is a highly selective, oral small-molecule inhibitor of KIT in clinical development for the treatment of severe allergic and mast cell-driven inflammatory diseases. The initial target indication for THB001 is for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts or hives. Chronic urticaria carries significant disease burden for patients, including decreased quality of life, impaired social and work function, depression and sleep disruption. Up to one percent of the U.S. population is believed to be affected by urticaria at some point in their lives.
In preclinical studies, THB001 demonstrated evidence of highly selective KIT inhibition and mast cell depletion in multiple tissue types. In early clinical studies, THB001 demonstrated dose-dependent reductions in serum tryptase, an established marker of mast cell activity and survival.
Beyond chronic urticaria, we plan to pursue development of THB001 in additional skin and respiratory indications in which mast cells play a known role in the pathophysiology and symptomatology of the disease.
We’re advancing THB001 for the treatment of multiple mast cell-driven inflammatory conditions that share similar pathophysiology, including dermal and respiratory diseases. THB001 is currently in clinical development for chronic urticaria, and we anticipate initiating a Phase 1b proof-of-concept study in
THB001 is in clinical development for chronic urticaria (also known as chronic hives), a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts or hives that develop in response to a specific stimulus (inducible urticaria) or with no known cause (spontaneous or idiopathic urticaria).
We do this together.
We keep going.